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Abstract: A mesoscopic physics-based optical imaging technique, partial wave spectroscopy
(PWS), has been used for the detection of cancer by probing nanoscale structural alterations
in cells/tissue. The development of drug-resistant cancer cells/tissues during chemotherapy
is a major challenge in cancer treatment. In this paper, using a mouse model and PWS, the
structural properties of tumor tissue grown in 3D structures by xenografting drug-resistant and
drug-sensitive human prostate cancer cells having 2D structures, are studied. The results show
that the 3D xenografted tissues maintain a similar hierarchy of the degree of structural disorder
properties as that of the 2D original drug-sensitive and drug-resistant cells.
© 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
1. Introduction
Elastic light scattering, especially in the visible range of light, is an important method for
probing structural morphologies of the biological cells/tissues. It is now shown that probing the
structural alterations at nano to submicron scale enables the prediction of several properties of
the physical condition of cells/tissues in normal and disease/abnormal states. Recent studies have
shown that the progression of carcinogenesis results in nanoscale structural alterations due to the
rearrangement of the basic building blocks, in particular, macromolecular components inside the
cells/tissues. This nanoscale structural alterations, in terms of the degree of disorder strength,
has been shown as an important biomarker in the determination of cancer stages [1,2]. However,
the histopathological examinations of cells/tissues, conventionally, are based on a large degree of
changes in the cellular architecture, mainly nuclear size, during the disease process [3–6]. Also,
the sensitivity of the existing pathological optical microscopic techniques used to detect such
nanoscale alterations are restricted by the diffraction limited resolution (>∼200 nm).
A recently introduced spectroscopic microscopy technique, partial wave spectroscopy (PWS),
which combines the interdisciplinary approaches of mesoscopic condensed matter physics and
microscopic imaging, to quantify the degree of change of the nanoscale structural disorder
of weakly disorder medium like biological cells/tissues [7–11]. The statistical quantifications
of the reflected intensities due to the nanoscale refractive index fluctuations of the biological
cells/tissues are carried out using the PWS analysis. In the PWS technique, the backscattering
signals from thin weakly disordered cell/tissue samples are divided into many parallel scattering
quasi one-dimensional reflections to calculate the structural disorder strength of the samples.
Further, the spatial variation of the intracellular components such as DNA, RNA, lipids, and
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extracellular matrices (ECM) gives rise to spatial mass density fluctuations in terms of the
refractive index fluctuations of the cells/tissues. This spatial refractive index fluctuations can
be quantified in terms of the degree of structural disorder. The degree of structural disorder
parameter Ld, called the disorder strength, can quantify nanoscale alterations and distinguish
different cancer stages with higher accuracy. For a quasi-1D approximation, the disorder strength
can be expressed as Ld =dn2×lc, where dn is the standard deviation (std) of the onsite refractive
index fluctuations dn(r) and lc is its spatial correlation length. The efficiency and application
of the PWS technique in measuring nanoscale alterations, i.e. the Ld parameter, to diagnose
diseases like cancer has been developed and explored [7–10,12,13]. The detection of molecular
specific structural disorder in submicron scales of control and cancer/abnormal cell nuclei are
also studied by the light localization technique using confocal microscopy, which support the
increase in the molecular specific structural disorder in progressive cancer [14–17].
After diagnosis of cancer, the cancer patient generally goes through chemotherapy drug
treatment. Resistant of cancer cells/tissues to chemotherapy drug is one of the obstacles to
cancer treatment. Recently, the PWS technique was successfully used to study the effect of
chemotherapy drugs on prostate cancer cell lines and to quantitatively measure the structural
disorder strength of drug-sensitive and drug-resistant prostate cancerous cells [8]. The results
show that the chemo-resistant cells have a higher degree of structural disorder than that of the
chemo-sensitive cells. Drug-resistant cancerous cells can survive through chemotherapy drug
treatment, as the different mechanisms and morphological structures developed are responsible
for drug resistance. These different morphological structures in drug-resistant cancer cells may
be due to the rearrangements of macromolecules, increase in the sizes of pores, architectural
differences of the cytoskeletal network, etc., which result in increasing aggressiveness and the
disorder strength.
Prostate cancer is one of the most prevalent types of cancer with one of the highest male
mortality rates in the USA. The American Cancer Society (ACS) estimates about 174,650 new
cases of prostate cancer will appear and account for a total of 31,620 deaths for 2019. Across the
globe, the statistical data of prostate cancer suggests that among every 9 men, one individual will
develop this cancer during his lifespan. Therefore, it is necessary to explore early and effective
diagnosis and treatment methods for prostate cancer. At present, chemotherapy is the only way
to treat metastasized prostate cancer, however, it is often found ineffective due to an individual
patient’s chemo-resistance that leads to tumor progression [8,18–22]. The PWS studies of
cancer cell lines have shown some promising success in distinguishing the hierarchy and drug
effectiveness based on the measurement of the biomarker, the structural disorder strength Ld [8].
These PWS studies of drug resistance cells were mainly focused on isolated cancer cells
which were grown in 2D on glass slides. However, in reality, a metastasized cancer cell grows
into a tumor with 3D structure when grown within the body, and these tumor cells may have
different structural properties due to its grown 3D tissue structures. This leads to a demand for
the development and quantitative characterization of 3D tumor tissues that are grown from the
drug-sensitive and drug-resistant cancer cells. This could establish a correlation between isolated
cells of 2D structure which is grown into tissue in 3D structure, based on the structural disorder.
In particular, we want to verify the structural properties of 3D tissues generated by xenografting
of cancer cells, and to understand any relationship between the 3D tissue structures with their
original 2D cell structures, using the Ld parameter. Human cancer cases have been studied by
innumerable murine methods and the determinants responsible for malignant transformation,
invasion, and metastasis, as well as the examination of the response to therapy is investigated
by the aid of these murine models. Xenografting of human cancer cells in a mouse model is
one of the most extensively used models to study the development of tumors from cells [23,24].
Cancerous human cells were subcutaneously injected in immunocompromised mice. Based on
the number of cells injected, the tumors will develop over 1-8 weeks and reaction to the proper
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therapeutic regimes can be studied in vivo [23,25] or ex vivo. At the same time, the structural
properties of growing xenografted cancer cells are not well studied.
In this work, using a further engineered PWS technique, we explore the structural properties of
the 3D tumor tissues obtained by xenografting drug-sensitive and drug-resistant human prostate
cancer cells (2D structures) using a mouse model. We study structural properties of tissues
obtained by xenografting two types of human prostate cancer (PC) cell lines, namely DU145 and
PC3, whose drug-resistant and drug-sensitive structural properties were studied earlier by the
PWS technique [8]. From the results, a correlation between the 3D structural disorder of tissues
original grown from chemotherapy drug-sensitive and drug-resistance cells and the original cells
will be performed. Finally, we will also discuss about the potential applications of the technique
in cancer diagnostics.
2. Method
2.1. PWS experimental setup
We perform the structural disorder measurement of tissues using a recently developed partial
wave spectroscopy (PWS) experimental technique, with further engineering of finer focusing
[7–9]. The PWS setup with a fine focus to measure the structural alterations at the nanoscale
level is as shown in Fig. 1. Xenon Lamp (Newport, 150W), a source of stable broadband white
light is used to illuminate tissue samples of micron thickness using Kohler Illumination. The
white light is reflected towards the combination of lenses with silver coated mirror (Thorlabs,
f= 50.8mm). The combination of converging lenses (Thorlabs, f= 50.8mm) along with the
apertures (Newport) form a 4f system that helps to minimize the diffraction effect and preserve
the high-frequency effect and hence enhances the sharpness in an image. This collimated light
from the lens is reflected by a right-angle prism (Thorlabs, 25.4mm) and passed through the
dichroic mirror (Thorlabs, 25.4mm) and then enters an objective lens (Newport, NA= 0.65,40X).
The low numerical aperture objective lens focuses the light in the sample within its working
distance with the help of high-resolution 3D electronic motorized stage (Zebar Tech, 100 nm in Z
axis and 40 nm in X-Y axis). This high-resolution motorized 3D stage is considered revolutionary
to the microscopic setup for its extreme accuracy and finer focus. A finer focus is essential for
correctly defining the effective scattering volume/length of a sample. The backscattered signal
from the sample is passed through the objective which gets reflected into the thick collecting
lens (Thorlabs, Φ=50.8mm) before the aperture. Finally, the collected backscattered signal
passes through a liquid crystal tunable filter i.e. LCTF (Thorlabs, KURIOS-WB1) with a spectral
resolution of 1 nm within the visible range (420-730 nm) of the spectrum. A CCD camera
(Retiga 3, 1460×1920) coupled with a LCTF controller records the filtered signal in the desired
wavelength range. Here, the CCD camera and LCTF filter are coupled with the LCTF controller
in such a way that for each 1 nm increment in wavelength by the LCTF filter (resolution 1 nm),
the backscattered signals are recorded in the CCD within the visible range.
2.2. Calculation of the structural disorder or disorder strength (Ld)
The backscattered images are recorded in the CCD camera at every wavelength (λ) at the spatial
pixel position (x, y) in the wavelength range 450-700 nm, and the reflected data cube, R(x, y;
λ), is acquired by the PWS system. Here, the data cube R(x, y;λ) includes the fluctuating
part of the reflection coefficient over the visible wavelength regime due to the presence of
a disordered medium including the high frequency noise. In a quasi-1D approximation, the
collected backscattered data at each (x, y) from R(x, y;λ) is fitted with a polynomial of the
5th order. The fitted polynomial is then extracted from the signal to remove the systematic
errors. In the next step, the R(k) signal for each pixel position (x, y) is obtained after applying a
fifth-order low-pass Butterworth filter with a suitable normalized cutoff frequency to remove the
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Fig. 1. Experimental layout of the partial wave spectroscopy (PWS) setup with nanoscale
structural alteration sensitivity. The green color represents broadband white light from the
source and red color after dichroic mirror is the backscattered signal.
high frequency noise components from the reflected signals of micron size samples. From the
extracted backscattered data cube, calibration of the system is done by matching the reflected
intensity pattern using a non-disordered system, NIST-traceable microspheres with the reflected
signal from a thin film slab model. The PWS measures the spectral fluctuation dividing the signal
from the sample into the collection of backscattered parallel channels. Based on the mesoscopic
optical property of the object, the spectral fluctuations originating from multiple scatterings of
the sample are analyzed.
The fluctuating part of reflection signals R(x, y;λ) arises due to the multiple interferences of the
photons reflected from the disordered medium. Since in a quasi-1D approximation, the sample
is virtually divided into many parallel channels within the diffraction limited transverse size
and the backscattered signals propagating along the 1D trajectories are collected. This optical
detection method is termed as the partial wave spectroscopy (PWS). The statistical properties
of nanoarchitecture are quantified at the nanoscale level by analyzing the fluctuating part of
the reflected intensities. The refractive index fluctuation information is collected from these
spectral fluctuations originated from the multiple scattering of the sample at any length scale
below the diffraction limit. The degree of structural disorder parameter Ld can be derived from
the rms value of the reflection intensity <R(k)>rms and the spectral auto-correlation decay of the
reflection intensity C(∆k) ratio. That means, for a given pixel at position (x, y), the degree of







Where B is the normalization constant, n0 is the average refractive index of the biological
cells/tissues, and k is the wavenumber (k = 2π/λ).
For the Gaussian color noise of the refractive index at position r and r’ <dn(r)dn’(r’)>=dn2exp(-
|r-r’|/lc), it can be shown that Ld=<dn2>lc [10,11]. The disorder strength quantifies the variability
of the local density of intracellular material within the samples, and hence the average and
standard deviation of the Ld are calculated to characterize the system.
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2.3. Sample preparation
Freshly collected prostate cancer (PC) cells from two different cell lines were used to develop
prostate xenograft mouse model. For the generation of tumor xenograft mouse models, 6–8 weeks
old male nude mice were implanted with PC3 (docetaxel-sensitive and docetaxel-resistant) and
DU145 (docetaxel-sensitive and docetaxel-resistant) human PC cell samples (2 × 106 cells per
mice), by subcutaneously injections. After tumors reached beyond the critical size of 1000 mm3,
they were excised from euthanized mice. The excised tumors were further paraffin embedded
and sectioned using microtome in 4µm thickness and placed on glass slides. Further, these slides
were processed for antigen retrieval process as described previously [26]. The resultant tumor
sections were subject to imaging studies.
3. Results
PWS detects the nanoscale structural alterations in the cells/tissues and can distinguish the
different levels and effects of the drug in the tumorous cells/tissues [11]. Among the different
types of cancer, prostate cancer is a major concern of public health at present because of its
low survival rate. Further, drug-resistant cancer cells are a prominent problem currently in
cancer treatment. Therefore, we focus our research to characterize the structure of tumor tissues
generated by the xenografting of chemotherapy drug-sensitive and drug-resistant prostate cell
lines, DU145 and PC3. For this, human drug-sensitive and drug-resistant prostate cancer
cells were subcutaneously injected in mice and allowed to grow and achieve the tumor size
of ∼1000mm3. After that, mice were euthanized, and tumors were excised then subsequently
processed to 4 µm thick tumor sections on slides for PWS imaging analyses.
PWS experiments, as described earlier, were performed on xenografted prostate tumor tissues
for each category on at least 3 different mice. All tumor tissue was obtained from different prostate
cancer cell lines xenografted into mouse models. For each tissue sample, PWS experiments were
performed on 7 different spots. In particular, for each category of a tumor, ∼60 different spots
are experimented with PWS and analyzed. The spectroscopic PWS experiments are performed in
the wavelength range 450-700 nm. The backscattered data matrix R(x, y; λ) are imported and the
disorder strength for each tissue is calculated using the PWS technique as described in section 2.2.
The disorder strength is calculated as the product of the variance and the spatial correlation length
of the refractive index fluctuations, Ld=<∆n2>lc. The average and standard deviation of the
disorder strength for each category is calculated in order to understand the physical properties of
a tumor developed as a 3D structure from a cell. The detailed PWS analysis of a tumor obtained
from a xenografted model of drug-sensitive and drug-resistant cell lines DU145 and PC3 are
explained below:
3.1. Structural disorder in the xenografted DU145 tumor tissue type
In Fig. 2, the PWS analysis of a tumor tissues obtained from xenografting drug-sensitive and
drug-resistant prostate human cancer cell lines of DU145 type are shown. From the PWS
experiment R(x, y, λ) data matrixes were obtained. At every pixel point (x, y), R(k)rms value and
corresponding C(∆k) were obtained, and from these two values, Ld value was calculated using
Eq. (1). The bright field images, as shown in Fig. 2(a)-(b), of the thin tissue samples developed
from drug-sensitive and drug-resistant cancer cell lines appear indistinguishable, whereas the
Ld images, as shown in Fig. 2.(a’)-(b’) are noticeably distinguishable. The red spots in the Ld
image represent a higher disorder strength, i.e. the Ld value of that pixel. It can be seen in the bar
graphs, Fig. 2(c) and 2(d), that there is an increase in the degree of structural disorder of tumor
tissue generated from xenografting drug-resistant cancer cells, compared to the tissues obtained
from xenografting drug-sensitive cancer cells. The average Ld value of a tumor obtained from a
drug-resistant cancer cell line is 9% higher than the tumor obtained from a drug-sensitive cancer
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cell line and the standard deviation std(Ld) is 8% higher. This result is in strong agreement with
the disorder strength calculated for drug-resistant and drug-sensitive cell lines earlier [8]. The
disorder strength of the prostate cancer cell line calculated using the PWS has shown that the
average and standard deviation of Ld values are higher in drug-resistant cells compared to the
drug-sensitive for DU145 type cells. The results confirm that the xenografted tissue structures
also have similar trends to original cell structures.
Fig. 2. (a) and (b) are the bright field images while (a’) and (b’) are the disorder strength,
Ld images of tissue obtained by xenografting drug-sensitive and drug-resistant PC cells line
of DU145 type respectively. (c) and (d) are the graphical representation of the mean and
standard deviation of Ld of tumor respectively. Result shows 9% higher in the mean Ld and
a 8% increase in std Ld in tumors developed from drug-resistant PC DU145 type cells line
than the drug-sensitive cells. P-value < 0.05.
3.2. Structural disorder in the xenografted prostate PC3 tumor tissue type
Figure 3(a)-(b) shows the bright field and Ld images of tumor tissues originated from drug-
sensitive and drug-resistant PC PC3 type cells. Based on intrinsic properties of the tissue, the
disorder strength Ld at each pixel of the individual tissue image is calculated and represented by
2D color maps in Fig. 3.(a’)-(b’). In the color map, red spots correspond to the higher structural
disorder strength present in the thin tissue structure (averaged along the z-direction of the sample).
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The bar graphs, 3(c) and 3(d), are the representation of the average and standard deviation of Ld
values with the standard error bars. The result shows 12% difference in the average local disorder
strength Ld and 15% difference in the std (Ld), between tumors obtained from drug-sensitive
and drug-resistant cell lines. The increment in the mean and standard deviation of Ld for tissues
collected by the xenografting of drug-resistant PC PC3 cells compared to the drug-sensitive cells
are consistent with the original cell structures. It is clear from the plots that the disorder strength
increases from drug-sensitive to drug-resistant xenografted tumor tissues. Earlier results using
PWS analysis show that PC PC3 cells are more aggressive than other cell lines and in the same
way drug-resistant PC cell lines have higher disorder strength than drug-sensitive PC PC3 cells.
Figures 2 and 3 show the results obtained using xenografted tissue samples also have the same
kind of disorder strength hierarchy to that of the original PC cells. In particular, a comparatively
higher structural disorder strength Ld for tumors obtained from drug-resistant PC3 PC cell line
Fig. 3. (a) and (b) are the bright field images and (a’) and (b’) are the disorder strength,
Ld images of tissues obtained by xenografting of drug-sensitive and drug-resistant PC cells
line of PC3 type respectively. (c) and (d) are the bar graph representation of the mean and
standard deviation of Ld of xenografted tumor respectively. Result shows 12% higher in the
mean Ld and 15% increase in std Ld in a tumor developed from drug-resistant PC PC3 type
cells line than the drug-sensitive cells. P-value < 0.05.
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than DU145 PC cell line is in strong agreement with their original PC cell line disorder strength.
This confirms that the degree of disorder strength Ld can be used as a marker to detect the cancer
stages or drug effects using 3D cancer tissue structure, similar to that of a cell line that is easy to
study.
4. Conclusions
The results indicate that tumor tissues grown by xenografting of PC cells resistant towards
docetaxel have a higher disorder strength Ld than the same tissues from drug-sensitive PC cells.
Since the disorder strength increases with the increase in the level of tumorigenicity, which implies
chemotherapy resistant cells are more aggressive than drug-sensitive cancerous cells. Cells
from the prostate or any other cancerous region that survived through drug exposure are more
aggressive and develop with the cell line’s hierarchy as: PC3>DU145 [8]. As an application
of the developed finer focusing PWS technique, we have studied the structural alteration in the
xenografted tissue morphology that are grown in a 3D environment from single cells that mainly
have 2D structures. The results show metastasize isolated 2D cancer cells grown to 3D tumors in
the body have similar structure and characteristics. The PWS analysis of 3D tissue slices confirms
xenografted tissues from drug-resistant tumors have a higher average and standard deviation of
disorder strength (Ld) than the drug-sensitive counterparts. Also, the obtained results follow a
similar hierarchy of the cell lines that are studied earlier [8].
Probable cause of structural properties of drug resistance cells/tissues and higher structural
disorder (Ld): Studies have shown that the progress of cancer disturbs the regular growth as
well as the structure of cells/tissues. Further, cells/tissues that survive through the chemotherapy
adapt themselves with the situation and develop different morphological structures resulting in
higher mass density fluctuation due to the rearrangement of macromolecules, larger pore sizes,
changes in cytoskeleton nanoarchitecture, etc. This results in a higher structural alteration in
drug-resistant PC cells than drug-sensitive ones. The different mechanisms such as: tumor derived
exosomes biogenesis and composition, DNA and histone damage/repair, anti-cancerous multidrug
inactivation, alteration in drug targets treatment, heterogeneity in cancerous cells/tissues, death
inhibition of cells/tissue, epithelial-mesenchymal transition and metastasis, etc. [27–31] are
making the cancerous cells/tissues drug resistant [8]. Xenografted tumor tissues that are obtained
using cells from drug-resistant and drug-sensitive PC cell lines, maintain the same types of
structural hierarchy properties when they are grown into 3D structures. This supports a strong
correlation in structural properties in 2D and 3D structures.
Applications of the developed technique for cancer treatment: The PWS study of xenografted
tissues obtained from drug-sensitive and drug-resistant PC cells line could establish a new insight
into advancing the understanding of the physical state and drug effectiveness on cancerous
cells/tissues at the nanoscale level, by knowing their structural properties. The xenografted
tissue structure replicating the structural properties of cancer cells explained statistically in term
of the disorder strength Ld parameter could be a reliable, easy, and quantitative approach to
diagnose chemo-resistance. This result seeks the potential application to monitor the effect of
chemotherapy drugs on cancerous tissues and to study the different levels of tumorigenicity
which can be obtained both, in-vitro and in-vivo methods. In summary, this method will help in
understanding the drug-resistant and drug-sensitive cells/tissues and their different stages in the
body, by examining their structural disorder properties.
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